241 related articles for article (PubMed ID: 24160903)
1. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
[TBL] [Abstract][Full Text] [Related]
2. Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.
Liu J; Kopečková P; Pan H; Sima M; Bühler P; Wolf P; Elsässer-Beile U; Kopeček J
Macromol Biosci; 2012 Mar; 12(3):412-22. PubMed ID: 22493797
[TBL] [Abstract][Full Text] [Related]
3. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.
Ray A; Larson N; Pike DB; Grüner M; Naik S; Bauer H; Malugin A; Greish K; Ghandehari H
Mol Pharm; 2011 Aug; 8(4):1090-9. PubMed ID: 21599008
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
5. HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.
Zhou Y; Yang J; Rhim JS; Kopeček J
J Control Release; 2013 Dec; 172(3):946-53. PubMed ID: 24041709
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
7. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
8. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.
Borgman MP; Aras O; Geyser-Stoops S; Sausville EA; Ghandehari H
Mol Pharm; 2009; 6(6):1836-47. PubMed ID: 19743884
[TBL] [Abstract][Full Text] [Related]
10. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
11. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
12. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
13. Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia.
Larson N; Gormley A; Frazier N; Ghandehari H
J Control Release; 2013 Aug; 170(1):41-50. PubMed ID: 23602864
[TBL] [Abstract][Full Text] [Related]
14. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.
Roy J; Nguyen TX; Kanduluru AK; Venkatesh C; Lv W; Reddy PV; Low PS; Cushman M
J Med Chem; 2015 Apr; 58(7):3094-103. PubMed ID: 25822623
[TBL] [Abstract][Full Text] [Related]
15. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
16. Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1).
Pooja D; Kulhari H; Adams DJ; Sistla R
Expert Opin Ther Pat; 2016 Jul; 26(7):745-9. PubMed ID: 27088623
[TBL] [Abstract][Full Text] [Related]
17. Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles.
Jin MJ; Piao SJ; Jin TX; Jin ZH; Yin XZ; Gao ZG
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):66-75. PubMed ID: 24496681
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.
Zhou Y; Yang J; Zhang R; Kopeček J
Eur J Pharm Biopharm; 2015 Jan; 89():107-15. PubMed ID: 25481033
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
